These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Zeidan AM; Sekeres MA; Garcia-Manero G; Steensma DP; Zell K; Barnard J; Ali NA; Zimmerman C; Roboz G; DeZern A; Nazha A; Jabbour E; Kantarjian H; Gore SD; Maciejewski JP; List A; Komrokji R; Leukemia; 2016 Mar; 30(3):649-57. PubMed ID: 26464171 [TBL] [Abstract][Full Text] [Related]
5. The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes. Castelli R; Schiavon R; Deliliers GL Med Oncol; 2018 Feb; 35(3):33. PubMed ID: 29417235 [TBL] [Abstract][Full Text] [Related]
6. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951 [TBL] [Abstract][Full Text] [Related]
7. Impact of age and comorbidity in myelodysplastic syndromes. Stauder R; Nösslinger T; Pfeilstöcker M; Sperr WR; Wimazal F; Krieger O; Valent P J Natl Compr Canc Netw; 2008 Oct; 6(9):927-34. PubMed ID: 18926101 [TBL] [Abstract][Full Text] [Related]
8. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome. Ritchie EK Clin Interv Aging; 2012; 7():165-73. PubMed ID: 22791989 [TBL] [Abstract][Full Text] [Related]
11. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461 [TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic strategies: hypomethylating agents and beyond. Santini V Hematology Am Soc Hematol Educ Program; 2012; 2012():65-73. PubMed ID: 23233562 [TBL] [Abstract][Full Text] [Related]
13. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany. Gattermann N; Kündgen A; Kellermann L; Zeffel M; Paessens B; Germing U Eur J Haematol; 2013 Dec; 91(6):473-82. PubMed ID: 24102637 [TBL] [Abstract][Full Text] [Related]
14. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Beran M Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661 [TBL] [Abstract][Full Text] [Related]
15. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience. Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450 [TBL] [Abstract][Full Text] [Related]
16. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies]. Aul C; Giagounidis A; Germing U; Ganser A Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275 [TBL] [Abstract][Full Text] [Related]
17. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Joeckel TE; Lübbert M Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063 [TBL] [Abstract][Full Text] [Related]
18. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. Tentori CA; Gregorio C; Robin M; Gagelmann N; Gurnari C; Ball S; Caballero Berrocal JC; Lanino L; D'Amico S; Spreafico M; Maggioni G; Travaglino E; Sauta E; Meggendorfer M; Zhao LP; Campagna A; ; Savevski V; Santoro A; Al Ali N; Sallman D; Sole F; Garcia-Manero G; Germing U; Kroger N; Kordasti S; Santini V; Sanz G; Kern W; Platzbecker U; Diez-Campelo M; Maciejewski JP; Ades L; Fenaux P; Haferlach T; Zeidan AM; Castellani G; Komrokji R; Ieva F; Della Porta MG; J Clin Oncol; 2024 Aug; 42(24):2873-2886. PubMed ID: 38723212 [TBL] [Abstract][Full Text] [Related]
19. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Grinblatt DL; Sekeres MA; Komrokji RS; Swern AS; Sullivan KA; Narang M Leuk Lymphoma; 2015 Apr; 56(4):887-95. PubMed ID: 24956145 [TBL] [Abstract][Full Text] [Related]
20. A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome. Asano M; Ohyashiki JH; Kobayashi-Kawana C; Umezu T; Imanishi S; Azuma K; Akahane D; Fujimoto H; Ito Y; Ohyashiki K Drug Des Devel Ther; 2019; 13():1821-1833. PubMed ID: 31239639 [No Abstract] [Full Text] [Related] [Next] [New Search]